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Abstract
Background: Current guidelines regarding Lyme neuroborreliosis [LNB] require the presence of intrathecal Borrelia
burgdorferi-specific antibody production for the definite diagnosis of LNB. However, about 20% of early stage
infections present without an elevated antibody index. Moreover, intrathecal B. burgdorferi specific antibody
synthesis may persist long after successful therapy of LNB. Recently published data indicate that CXCL13 seems to
be a promising diagnostic tool for early stage LNB. In addition, CXCL13 might be suitable for treatment monitoring.
Case presentation: We report on a 39-year-old male patient from southern Germany, who has been suffering from
subfebrile body temperatures and meningeal headache for six weeks. On the second day after hospital admission
he developed peripheral palsy of the VII. cranial nerve. Cerebrospinal fluid (CSF) analysis showed granulocytic
pleocytosis, elevated total protein and blood-CSF barrier dysfunction. Differential diagnostics for granulocytic
pleocytosis were unremarkable. Only a second lumbar puncture, on day 6 after admission, revealed a lymphocytic
pleocytosis. Serologic testing pointed to clear intrathecal Borrelia specific IgG antibody production. Interestingly, no
anti-OspC antibodies were detectable. DNA of the rare Borrelia garinii OspA-type 7 could be amplified from the first
CSF sample. The monitoring of CXCL13 in all CSF samples documented a fast decrease from 5000 pg/ml to 450 pg/ml
after appropriate antibiotic treatment.
Conclusion: CXCL13 is a novel biomarker with high sensitivity and specificity for acute LNB. Our data show, that
CXCL13 might be helpful in unclear cases and support the presumption that it might be a valuable tool for treatment
monitoring. Anti-OspC antibody negativity is a rare observation, given the need of OspC for infection of the human
hosts. Most likely this is due to a lack of sensitivity of OspC immunoblots that are unable to detect rare OspC variants.
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Background
The multisystem disease Lyme borreliosis (LB), mainly
affecting skin, nervous system and joints, is the most
frequently reported vector-borne disease in the temperate
zones of the Northern Hemisphere. In Europe at least five
different genospecies – namely B. burgdorferi sensu stricto,
B. afzelii, B. garinii, B. spielmanii, and B. bavariensis –
may cause human diseases. The most frequent dissemi-
nated form of the disease is early Lyme-neuroborreliosis
[LNB]. Current international guidelines [1] require the
presence of intrathecal B. burgdorferi-specific antibody
production for the definite diagnosis of LNB. However,
about 20% of early stage infections initially present without
a positive antibody index. Moreover, B. burgdorferi specific
intrathecal antibody synthesis may persist a long time after
successful therapy of LNB in terms of an “anamnestic
titer” that will not allow differentiation of active from past
disease. The chemokine CXCL13 (Chemokine C-X-C
motif ligand 13) is known to influence homing and motility
of B cells in lymphoid tissue and is involved in the forma-
tion of ectopic lymphoid tissue in chronic inflammation [2].
Recently published data [3] indicate that B cell-attracting
CXCL13 seems to be a promising diagnostic tool for diag-
nosis of early stage LNB. In addition, CXCL13 might be
suitable for the monitoring of therapy.
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Case presentation
A 39-year-old male and otherwise healthy patient pre-
sented in the emergency department with a history of
6 weeks of headache radiating to the neck and spine.
The patient felt repeatedly hot flashes without reaching
febrile temperature levels. On admission he also
reported nausea without vomiting. The patient had no
known allergies, no history of insect or animal bites, he
had travelled to northern Italy 2 weeks before onset of
the symptoms. One week before onset he had recieved
surgical treatment of an axillary abscess under local
anaesthesia. In the first two weeks of subfebrile tempera-
tures and headache, he consulted his family doctor.
Laboratory testing at his visit showed normal results
for white blood-cell count and differential cell count,
C-reactive protein, and serological tests for HIV, Borrelia,
Yersinia, Chlamydia and Campylobacter. Results of testing
for antinuclear antibodies [ANA], antineutrophil cytoplas-
mic antibodies [ANCA] and urinanalysis were normal.
Magnetic resonance imaging [MRI] of the brain with
administration of contrast material revealed no signs of
inflammation, malignancies or vascular complications.
The patient received an eight day therapy of steroids -
70 mg prednisolone per day – resulting in a transient im-
provement of his condition. However, 10 days before
admission to this hospital his headache worsened again.
On admission to our hospital the temperature was
38.5°C, stable vital signs, blood pressure 140/75 mmHg,
heart rate 70 beats per minute, oxygen saturation 97%
while breathing ambient air. The weight was 79.5 kg. The
skin was warm and dry. The abdomen was soft, normal
bowel sounds, without distention, tenderness or masses.
Neurological examination revealed positive meningeal
signs, the remainder of the examination was normal.
Echocardiography points to a mild pericardial effusion,
while the electrocardiogram was normal - apart from non-
specific ST-segment changes. Standard laboratory tests
were repeated, without significant findings [negative pro-
calcitonin, negative C-reactive protein, normal white cell
count]. On the second hospital day, the patient developed
a right sided peripheral palsy of the VII. cranial nerve. An
emergency MRI of the brain was performed, but did not
show any significant pathological intracranial findings.
Cerebrospinal fluid [CSF] analysis showed 280 cells,
predominantly granulocytes [70%] and lymphocytes
[20%], lactate and CSF total-protein levels were elevated,
microscopic examination and gram staining revealed
no bacteria in CSF [Table 1.]. Treatment with acyclovir
[5 × 800 mg /d], ceftriaxon [2 × 2 g /d] and ampicillin
[3 × 5 g /d] was promptly initiated.
The nuclear acid testing [PCR] for HSV1, HSV2 and
VZV in CSF was negative, there was no detection of
enterovirus nuclear acid in the patient plasma, no clini-
cal and laboratory signs of CNS HIV or Treponema
pallidum infection were observed. CMV and EBV ser-
ology showed positive IgG titers, whereas IgM titers
were negative. Additional screening for Coxiella burnetii,
Brucellosis and Tuberculosis [IGRA, CSF microscopy
and CSF PCR] remained negative. Borrelia serology was
not done regarding predominant granulocytes in the
CSF. To rule out neurosarcoidosis or systemic sarcoidosis
a total body Computed Tomography [CT] was performed,
but without any significant findings, in particular neop-
terin, soluble IL-2 receptor [sIL-2r] and angiotensin con-
verting enzyme [ACE] were not suggestive for sarcoidosis.
The follow-up lumbar puncture [see Table 1] noted
pleocytosis with now predominantly lymphocytes. Total
CSF-protein levels decreased from 2470 mg/l to 1510 mg/l.
The total CSF cell count showed an increase to 360 cells –
Fluorescence Activated Cell Sorting [FACS] analysis was
used to ruled out clonal expansion of hematological cells in
the CSF and cytologic analysis did not detect any malignant
cell formations.
In view of lymphocytic CSF pleocytosis and facial
palsy, Borrelia serology was repeated. Now the Borrelia
specific CSF/serum IgG-antibody index (AI) was clearly
positive, valued 20.6. The intrathecal Borrelia specific
antibody production was further confirmed by IgG- and
IgM-adjusted Immunoblots based on recombinant anti-
gens (recomBlot, Mikrogen, Martinsried, Germany).
Here, for both, IgG and IgM, clearly stronger reactive
bands were visible in the CSF compared to serum
(Figure 1). Routine PCR from CSF targeting ospA of
B. burgdorferi was negative. All three criteria required
in current guidelines for the definite diagnosis of LNB
were met [see Table 2.]: I. neurological symptoms suggest-
ive for LNB, II. CSF pleocytosis and III. B. burgdorferi spe-
cific intrathecal antibody production [1]. At this point
antiinfective treatment was adjustet to i.v. monotherapy
with ceftriaxone 2 g q24 for 21 days.
For an additional diagnostic workup, specimens of
the first two lumbar punctures and a third follow-up
CSF sample were further investigated at the German
National Reference Centre for Borrelia. Levels for CXCL13
were markedly elevated in the first two CSF samples,
i.e. 5000 pg/ml and 2000 pg/ml. The cut-off range of
the assay used is set at 100 - 250 pg/ml according to
recent studies that reported sensitivities between 88%
and 98% and specificities between 89% and 98% [4,5].
In the third liquor sample, after the patient received
appropriate antbiotic therapy, CXCL13 levels have
already been decreased to 450 pg/ml [see Table 1]
and CSF cell count dropped to 190 cells. However,
cranial nerve palsy was persisting, without signs of
clinical improvement. Advanced in-house OspA and
p41 PCR diagnostics with several highly specific pri-
mers were positive in the first CSF specimen. Ampli-
fication and sequencing of the complete OspA gene
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identified B. garinii OspA-type 7, an overall rarely
detected subtype, as the causative agent.
Immediately after the completion of antibiotic treat-
ment the patient felt good without meningeal signs and
the peripheral facial palsy was slowly improving. Two
month after being discharged, a follow up lumbar punc-
ture [see Table 1.], revealed slowly decreasing levels of
intrathecal Borrelia-specific antibody production and a
CXCL13 at 52.8 pg/ml, now clearly below the threshold
for LNB. There were no clinical signs of cranial nerve
palsy left.
Discussion and literature review
The chemokine CXCL13 is a promising biomarker for
early untreated LNB [3,6,7]. Here we report on one of
the first prospectively monitored cases with confirmed
LNB. There are several retrospective studies showing
elevated levels of CXCL13 in patients with untreated
early LNB even before Borrelia-specific antibodies could
be detected intrathecally. To prove intrathecal produc-
tion of Borrelia-specific antibodies, calculations that
consider blood/CSF-barrier dysfunctions [AI] are used.
The first prospective study on the role of CXCL13 was
published recently, indicating excellent sensitivity
[94.1%] and specificity [96.1%] in the diagnosis of LNB
using a different CXCL13 assay at a threshold value of
1.229 pg/ml for CXCL13 in the CSF. In comparison AI
was less sensitive than CXCL13 [94.1% vs. 85.7%], whereas
specificity of both markers was almost equal [3]. However,
only 4 patients with untreated LNB had prospectively
been enrolled, 10 patients pretreated and additional 13
patients had only been retrospectively analyzed [3].
CXCL13 is measurable in early untreated LNB even
before borrelia-specific intrathecal antibody production
has started. The hypothesis for this finding is a sequen-
tial chain of events that is assumed to happen before
intrathecal antibody production starts: After invading
the CNS, spirochetes interact with human monocytes,
macrophages and dendritic cells, where CXCL13 pro-
duction is induced via toll-like receptor 2 [TLR-2] acti-
vation [8]. CXCL13 then attracts and activates B-cells,
which migrate into the CSF and only subsequently start
producing (specific) intrathecal antibodies. In pretreated
patients, by contrast no or only minimal elevations of
CXCL13 levels were observed, pointing to a rapid down-
regulation of CXCL13 production after specific anti-
biotic therapy is initiated [9]. Our results match this
hypothesis perfectly. In the first CSF a granulocytic pleo-
cytosis was detected, indicating a very early phase of
neuroborreliosis as aseptic meningitis [10], that already
presented with very high levels of CXCL13, which
dropped to only 40% of the initial value within three
days. Therefore our results are consistent with earlier
reports showing CXCL13 decreases under appropriate
anti-infective treatment, suggesting the elimination of
the causative bacterial agent. The fact that CXCL13 has
dropped during the first days of appropriate treatment,
while the CSF cell-count further increased, leads us to
the presumption that CXCL13 measurements might be
superior to follow-up cell-count examinations in this re-
spect. However, in current guidelines [1] for the treat-
ment of LNB no recommendation for routine use of
CXCL13 is noted. CXCL13 is a promising new bio-
marker, but further research is needed to determine
whether different species of Borrelia affect the CXCL13
response equally [6]. It has been shown, that B.afzelii
induces CXCL13 production in a similar manner [11].
There are only limited data yet available regarding
this aspect. In Europe LNB is predominantly evoked by
B. garinii [3,12], whereas in North America B. burgdorferi
sensu stricto is the only human pathogenic species, which
has different clinical and neuroinflammatoric features
from B. garinii. Here we demonstrate that, regarding
B. garinii - at least CNS-infection with OspA type7 -
leads to a strong upregulation of CXCL13. Other CNS
prone spirochetes like Treponema pallidum induce similar
CXCL13 levels in acute untreated CNS infections. Previ-
ous studies also showed, that CXCL13 might be an useful
marker for neurosyphilis, particularly in HIV positive
patients with a negative VDRL test [5,13]. However,
CXCL13 levels in bacterial or viral meningitis mostly
remain under the cutoff [3,13]. Primary and secondary
CNS malignancies, like meningeal carcinomatosis, mul-
tiple sclerosis, as well as Cryptococcus neoformans CNS
Table 1 Cerebrospinal fluid analysis
1.CSF sample [day2] 2.CSF sample [day6] 3.CSF sample [day12] 4.CSF sample [day55]
CSF cells [/μl] 282 364 197 18
CSF Protein [mg/l] 2470 1510 1110 673
CXCL 13 [pg/ml] 5000 2000 450 52.8
CSF lactate [mmol/l] 3.38 2.72 2.24 -
CSF lymphocytes [%] 20 80 90 -
CSF monocytes [%] 10 10 10 -
CSF granulocytes [%] 70 10 0 -
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infections and congenital toxoplasmosis may lead to
CXCL13 levels as noticed in untreated LNB [5].
A second interesting aspect of the current case is anti-
OspC antibody negativity. OspC is an essential outer
surface protein [Osp] for the establishment of the infec-
tion and dissemination of the pathogen in humans [14].
The commercial Borrelia immunoblot used in our routine
diagnostics [recomBlot, Mikrogen] showed no OspC-
specific bands using recombinant OspC Bg1, Bg2 or Bsa
antigens. The additional IgG- and IgM-immunoblots that
have been performed at the National Reference Centre for
Borrelia, using further OspC variants from different
strains [B. burgdorferi sensu stricto strain B31, B. afzelii
strain PKo, B. bavariensis strain PBi, B. garinii type strain
20047] did not show positive results, too [15]. In early
disseminated Lyme Borreliosis OspC negativity is an
uncommon phenomenon and B. garinii OspA serotype 7
is rarely isolated in LNB. In our opinion the most probable
explanation for the present case is insufficient sensitivity
of our tests because the respective antigen or OspC-
epitope is not present in the recombinant proteins used.
B. garinii OspA type 7 is all in all only rarely present [16].
Less than 5% of the infected ticks and B. burgdorferi CSF
isolates from Germany are positive for OspA serotype 7
[12]. Therefore it is not surprising, that the genetically
highly variable protein could not be reliably detected with
our immunoblots we applied, which do not contain this
specific OspC. In contrast OspA is highly conserved and
is used for advanced species subtyping [17,18]. Whether
recombinant antigens of rare strains should be added to
conventional immunoblots for optimal diagnosis of LNB
remains an open question. From an epidemiological point
of view, B. garinii is the most common agent in LNB.
There are different possibilities to explain the unusual
findings in our patient, i.e. granulocytic pleocytosis, posi-
tive IgG ELISA, negative IgM ELISA test and only slightly
positive immunoblot for IgM. Steroid pretreatment has
been associated with a suppression of sufficient IgG
production in animal models of LNB, whereas IgM
production has been less affected [19]. It remains un-
clear, whether the aforementioned eight day prednisone
pretreatment has interacted with the specific immune
response in this particular case. Early CNS dissemination
and evasion of the peripheral immune response is an add-
itional hypothesis for the weak peripheral immune re-
sponse compared to the strong intrathecal antibody
production. Pleocytosis with predominantly granulocytes
is a rare and deceptive observation. Especially in very early
stages of LNB or in immunosuppressed hosts there are
cases of inconsistent CSF cell count findings. B. afzelii
might even cause LNB with normal CSF cell counts [20].
Table 2 Criteria required for the definite diagnosis of LNB
[all three criteria fulfilled], possible diagnosis of LNB [two
of three criteria fulfilled] [1]
Criteria Patient symptoms in case report
neurological symptoms suggestive
for LNB
Peripheral paresis of the VII.
cranial nerve












Figure 1 IgG lineblot [recomBlot, Mikrogen]; Serum 1:271
dilution; CSF sample, 1:10 dilution. Both samples with equal total
IgG-concentrations (27 mg/l). Figure 1B IgM lineblot [recomBlot,
Mikrogen]; Serum sample diluted 1:3800; CSF sample diluted 1:10.
Both samples with equal total IgM-concentrations (0.392 mg/l).
Results from CSF analysis were positive for borrelia specific
intrathecal IgG antibody production. The intensity of the reactive IgG
and IgM bands [Optical Density, OD] was significantly stronger in
the CSF sample than in the serum and the specific antibody index
[AI] was strongly positive with 20.6.
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The cause of granulocytic pleocytosis and the quick shift
to predominantly lymphocytes in the CSF samples of the
above mentioned patient remain unclear.
Conclusion
In conclusion, the presented case demonstrates the effi-
cient use of CXCL13 in diagnosis and follow-up of LNB,
even with initial misleading findings. Possible pitfalls in
problematic cases, due to uncommon serological findings
or lack of species differentiation, underscore the need for
an interdisciplinary collaboration between neurologists,
infectious disease consultants and microbiologists.
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